Peter Attia on Peptides: Which Criticisms Actually Hold Up

Peter Attia recently gave peptides an entire podcast episode, and he was not gentle. He set out five questions he says any compound should survive before you put it in your body, then walked BPC-157 and CJC-1295 through them. In his reading, both fall short.

The reply came from Dr. Alex Tatem, a urologist who works with these compounds and whose group presented dispensing data at the recent FDA advisory committee meeting. His argument is not that Attia has the data wrong. It is that Attia is applying a test much of your medicine cabinet would also fail, and that the reason peptide trials do not exist has more to do with patent law than with biology.

Both men are partly right, and the disagreement is worth walking through slowly.

The five questions Peter Attia asks about peptides

Attia's framework is not peptide-specific. He proposes it for anything you might take:

1. Is there a viable mechanism of action?
2. Is there evidence of meaningful benefit in humans?
3. Do we understand safety, dosing and pharmacokinetics?
4. Does the likely benefit justify the risk for this person?
5. Is there a better characterized way to get the same result?

His reasoning on the first question is worth stating at full strength, because it is the fairest thing in the episode. A real mechanism forces a claim to become falsifiable. It asks what the molecular target is, what changes downstream, and why that would plausibly produce the effect being advertised. Without that chain, a phrase like "supports recovery" or "reduces inflammation" can mean almost anything, which in practice means it is marketing language. Anyone who has read peptide vendor copy knows exactly the problem he is describing.

The problem is how the five questions get used. Attia treats a "no" on any single one of them as ending the conversation.

Mechanism of action is a weaker filter than Attia suggests

Tatem's first counter is legal rather than scientific. Mechanism of action is not required for a drug to be approved in the United States. Section 505(d) of the Food, Drug and Cosmetic Act asks for substantial evidence of effectiveness plus adequate safety data, and mechanism appears nowhere in the text.

The examples are not obscure. Aspirin was in routine use for roughly seventy years before the prostaglandin work of 1971 explained it. Acetaminophen was long attributed to the cyclooxygenase pathway, an account now thought to be wrong, with a metabolite called AM404 acting on cannabinoid receptors as the current candidate. Intravesical BCG, approved in 1990, involves putting attenuated bacteria into a patient's bladder to turn their own immune system against bladder cancer. It is standard of care, and clinicians are still arguing about how it works. General anesthesia is given millions of times a year without a clean molecular story for how consciousness switches off.

Attia concedes at one point that about 3% of approved medicines have no known mechanism. Tatem's view is that the concession badly understates how common the situation is.

There is also a problem with the logic. Mechanism and human outcome data work as substitutes for one another, not as a pair you need both halves of. Aspirin ran on outcomes alone and patients did fine. Requiring both raises the bar above what the regulator itself requires.

BPC-157 human trials: where the criticism lands

This is the strongest part of Attia's case against the peptide evidence base, and it deserves to be reported accurately rather than argued away.

His summary of the literature is fair. Nearly everything claimed for BPC-157 comes from animal models. More than 80% of the published positive literature traces back to a single academic group, and researchers connected to that work hold intellectual property tied to the molecule. That does not make the findings false, but it does raise the bar for independent replication, and replication has been thin. After roughly three decades of claims, there is still no published peer-reviewed randomized human trial showing that BPC-157 accelerates healing.

Tatem does not dispute the headline. He argues that thin is not the same as absent, pointing to published case series, a study of BPC-157 instilled into the bladder for interstitial cystitis, and another examining intra-articular injection in chronic knee pain. On mechanism he cites a 2026 paper describing a specific route: BPC-157 engaging the E3 ubiquitin ligase adapter FBXO22 through a proline residue, which prevents the degradation of BACH1, a known regulator of blood vessel growth. Whether that finding replicates is a separate question, but "no mechanism at all" is no longer an accurate description.

The one large human dataset is a dispensing record rather than a trial. Testimony at the FDA advisory meeting covered roughly 16 million doses of BPC-157 dispensed over nine years, against seven adverse reports, all mild and mostly injection-site reactions. That figure is worth knowing and worth discounting in the same breath: passive reporting captures a small fraction of what actually happens, and a clean safety record says nothing about whether a compound works. Our BPC-157 monograph and the earlier piece on what the BPC-157 evidence shows go through the study-by-study picture.

Why the trial nobody ran is an economics story

In 2013 the US Supreme Court ruled 9-0 in the Myriad Genetics case that naturally occurring DNA sequences cannot be patented. The reasoning extends to the naturally occurring products of those sequences, which includes peptides like BPC-157. No company can own the molecule itself.

Attia anticipates this and answers that companies can still patent salts, manufacturing processes, delivery systems and dosing regimens. He is right that those patents exist, and some do cover BPC-157. Tatem's reply is that none of them is a composition-of-matter patent, and composition of matter is the only kind that funds a registrational program. Give a competent competitor a different synthesis route and eighteen months, and a process patent becomes decoration. Nobody commits $500 million to $1 billion to defend an exclusivity a rival can simply walk around.

Market size compounds the problem. A phase 3 trial needs an indication, and the honest indication here might be something like elbow tendinopathy resolving two weeks sooner. No insurer is waiting to pay for that, and a patient whose knee hurts rather than their elbow would fall outside the approved label anyway.

Attia reads the absence of a pharmaceutical race as telling you everything you need to know. It tells you that nobody has found a way to profit from the molecule, which is a different claim from saying the molecule does nothing. A gap in the peptide evidence produced by missing funding is still a gap, and testimonials do not close it. But waiting for the trial to arrive means waiting for something the patent system gives nobody a reason to run. The same structural problem sits behind most of the tissue repair compounds people ask about.

CJC-1295 and what "better characterized" actually costs

The fifth question assumes the better-characterized option is actually available. On CJC-1295, Attia asks why anyone would reach for it when growth hormone exists, or when tesamorelin exists, and whether CJC-1295 produces any measurable benefit.

The first answer is legal. Prescribing growth hormone off-label in the United States has been a felony since the Anabolic Steroid Control Act of 1990, so for most patients it is not an option a physician can offer at all.

The second is arithmetic. Tesamorelin runs longer than 40 amino acids, which places it in the biologic category rather than the peptide category, and the pricing follows the classification. Tatem quotes roughly $11,000 to $12,000 for a month's supply at 2 mg daily, with no retail discount listing to soften it. CJC-1295 sits under the 40-amino-acid line, which is why compounding pharmacies could supply it at ordinary prices if it reaches the relevant bulk substance list. The comparison with tesamorelin is less about pharmacology than about which regulatory bucket a molecule lands in.

On whether CJC-1295 does anything, both compounds raise IGF-1, and tesamorelin's own trials showed visceral fat reduction through that pathway. Tatem adds that CJC-1295 was shelved because its developer restructured through bankruptcy and chose to put its money behind long-acting GLP-1 drugs instead. The program ended for commercial reasons rather than clinical ones, which is worth knowing without mistaking it for evidence of benefit.

Key takeaways

• Attia's five questions are a reasonable filter, but a "no" on mechanism alone does not settle anything. US law does not require mechanism for approval, and several everyday drugs would fail that question.
• His criticism of the BPC-157 evidence base is accurate. After roughly thirty years there is still no published randomized human trial for accelerated healing.
• The positive literature is concentrated in one research group with commercial interests in the molecule, which raises rather than lowers the bar for replication.
• The missing trials track patent economics. Without a composition-of-matter patent on a natural sequence, no company will fund a phase 3.
• Cost and law decide what "a better-characterized alternative" means in practice. Growth hormone is unavailable off-label, and tesamorelin's price puts it beyond most people.

This article is based on "Peter Attia vs. Peptides: A Doctor Responds" by Dr. Alex Tatem: https://www.youtube.com/watch?v=raPPwAt9ZJg

This article is for educational purposes only. The peptides discussed are research compounds, and nothing here is medical advice. Always consult a qualified healthcare professional before making decisions about your health.